Incidence and severity of immune-related hepatitis after dual checkpoint therapy is linked to younger age independent of herpes virus immunity

Incidence and severity of immune-related hepatitis after dual checkpoint therapy is linked to younger age independent of herpes virus immunity

Abstract Background and Aims Dual immune checkpoint blockade (ICB) therapy can result in immune-related-adverse events (irAE) such as ICB-hepatitis. An expansion of effector-memory (TEM) CD4 T cells associated with antiviral immunity against herpesviridae was implicated in ICB-hepatitis. Notably, th...

Full description

Bibliographic Details
Main Authors: Zhen Zhang, David Rafei-Shamsabadi, Saskia Lehr, Nico Buettner, Rebecca Diehl, Daniela Huzly, David J Pinato, Robert Thimme, Frank Meiss, Bertram Bengsch
Format: Article
Language:English
Published: BMC 2022-12-01
Series:Journal of Translational Medicine
Subjects:
Checkpoint therapy
Immune-related adverse effects
Hepatitis
Age
Herpes virus
Online Access:https://doi.org/10.1186/s12967-022-03755-3

Internet

https://doi.org/10.1186/s12967-022-03755-3

Similar Items